2nd Next Generation Kinase Inhibitors Summit

Kongressthemen
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences

https://go.evvnt.com/1446853-3?pid=4832

Herr Min Ratcliffe